Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

PHP still 'best option' for Assura despite new KKR bid, says Shore Capital

(Sharecast News) - Shore Capital has retained a 'hold' rating for Assura following the news that the company has accepted an increased cash offer from KKR, saying that alternative suitor Primary Health Properties still represents the "best option" for shareholders. The healthcare property investment and management firm said on Wednesday that it has agreed to an increased and final 52.1p-a-share offer from from KKR and Stonepeak valuing the company at around £1.7bn.

The announcement comes days after Assura said due diligence in relation to a rival 51.7p takeover proposal from Primary Health Properties was still ongoing, with both parties "working closely" together.

According to Shore Capital analyst Andrew Saunders, the best option for Assura's shareholders would be to reject the KKR/Stonepeak big and accept the PHP offer and remain invested in a listed company, with the merger of the two complimentary businesses creating "a new powerhouse in a sector with attractive long-term growth prospects".

"While the new offer marginally exceeds that of PHP for the here and now, as we have consistently sad, the real value of PHP's offer stems from remaining listed. We continue to believe that PHP provides the best option for Assura shareholders with the recent trading update presenting a picture of Assura as a business performing well, with rents accelerating, development picking up, EPRA NTA growing and prospects looking brighter," Saunders said.

"Shareholders must surely now ask themselves why now would be the best time to leave the Assura journey?... accepting that the [KKR/Stonepeak] cash offer materially undervalues the business (placing no value on the operating platform or debt book) and hands the business at the bottom of the cycle to private equity, leaving them to benefit from the future double-digit returns."

Assura shares were up 2.1% at 49.94p by 1045 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.